{"id":3861,"date":"2023-11-22T13:41:23","date_gmt":"2023-11-22T18:41:23","guid":{"rendered":"https:\/\/www.medteq.ca\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/"},"modified":"2025-01-20T16:51:11","modified_gmt":"2025-01-20T21:51:11","slug":"innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients","status":"publish","type":"post","link":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/","title":{"rendered":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients"},"content":{"rendered":"<h1>Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients<\/h1>\n<div class=\"page-wrapper\">\n<div class=\"sections-container\">\n<article id=\"post-92323\" class=\"page-body style-light-bg post-92323 post type-post status-draft format-standard has-post-thumbnail hentry category-uncategorized\">\n<div class=\"post-wrapper\">\n<div class=\"post-body\">\n<div class=\"post-content un-no-sidebar-layout\">\n<div id=\"row-unique-1\" class=\"vc_row row-container boomapps_vcrow\" data-parent=\"true\" data-section=\"1\">\n<div class=\"row limit-width row-parent\" data-imgready=\"true\">\n<div class=\"wpb_row row-inner\">\n<div class=\"wpb_column pos-top pos-center align_left column_parent col-lg-12 boomapps_vccolumn single-internal-gutter\">\n<div class=\"uncol style-light\">\n<div class=\"uncoltable\">\n<div class=\"uncell boomapps_vccolumn no-block-padding\">\n<div class=\"uncont\">\n<div class=\"uncode_text_column\">\n<ul type=\"disc\">\n<li>\n<h5><strong>A remote patient monitoring mobile app and a digital therapeutics solution demonstrates its impact for the Quebec Public Healthcare System<\/strong><\/h5>\n<\/li>\n<li>\n<h5><strong>Heart failure outpatients achieved a significant reduction in emergency room visits and\/or hospitalizations<\/strong><\/h5>\n<\/li>\n<li>\n<h5><strong>Detailed data were presented at the 2023 American Heart Association\u2019s Scientific Sessions<\/strong><\/h5>\n<\/li>\n<\/ul>\n<p><span class=\"legendSpanClass\"><span class=\"xn-location\">MONTREAL<\/span><\/span>,\u00a0<span class=\"legendSpanClass\"><span class=\"xn-chron\">Nov. 21, 2023<\/span><\/span>\u00a0\/CNW\/ \u2013\u00a0The CONTINUUM program, a remote patient monitoring and digital therapeutics project led by\u00a0The Centre hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), helped heart failure outpatients achieve a significant reduction in the number of emergency room visits and\/or hospitalizations and demonstrated a 23% reduction in healthcare costs, according to preliminary results presented at the American Heart Association\u2019s Scientific Sessions, held November 11\u201313, 2023, in\u00a0<span class=\"xn-location\">Philadelphia, Pennsylvania<\/span>.<sup>1<\/sup><\/p>\n<p>There is increasing use of digital health solutions in heart failure, but few studies have demonstrated its impact on public healthcare systems in\u00a0<span class=\"xn-location\">North America<\/span>. Heart failure is on the rise with 750,000 Canadians living with the disease and more than 100,000 receiving a diagnosis each year.<sup>2<\/sup>\u00a0Heart failure is one of the top reasons why people in\u00a0<span class=\"xn-location\">Canada<\/span>\u00a0are hospitalized.<sup>2<\/sup>\u00a0By 2030, the healthcare costs associated with heart failure in\u00a0<span class=\"xn-location\">Canada<\/span>\u00a0are expected to reach\u00a0<span class=\"xn-money\">$2.8 billion<\/span>\u00a0per year.<sup>2<\/sup><\/p>\n<p>The three-month randomized controlled trial for heart failure outpatients at risk of hospitalization evaluated the CONTINUUM\u00a0program versus standard of care alone. This program included: 1. A self-care app via smartphone or tablet where patients entered vital signs, weight, and heart failure symptoms; 2. Remote monitoring of these data by the CHUM\u2019s clinical nurses; 3. Digital therapeutics automated medication suggestions sent to the treating medical team; and 4. Heart failure educational modules for patients \u2013 all based on Greybox Solutions\u2019 Takecare platform.<\/p>\n<p>The preliminary results show that the number of ER visits and\/or hospitalizations (all cause) per patient was 0.19\u00b10.47 for the intervention group and 0.55\u00b10.89 for the control one (P=0.05). Survival analysis showed a trend in favor of the intervention group (95 days (CI95% 87-104) vs 78 days (CI95% 68-89); P=0.08). The total cost of healthcare consumption (hospitalizations + ER visits) in the intervention group was\u00a0<span class=\"xn-money\">$134,088<\/span>\u00a0CAD vs\u00a0<span class=\"xn-money\">$174,924<\/span>\u00a0CAD in the control group (+30%).<\/p>\n<p>\u201cGiven the prevalence of heart failure and the seriousness of the condition, there is a real need for innovative solutions that can help improve patient outcomes and quality of life,\u201d says Dr. Fran\u00e7ois\u00a0<span class=\"xn-person\">Bernard Tournoux<\/span>, Cardiologist at the CHUM, Associate Professor, University of Montr\u00e9al, FRQS Clinical Researcher at the CHUM Research Centre and principal investigator of the trial. \u201cThe encouraging preliminary results from the CONTINUUM trial support further study in preventing major heart failure events, involving patients as partners in care, all at a reduced cost for the healthcare system.\u201d<\/p>\n<p>A total of 171 patients were included in the trial. Preliminary results are available for the first 63 patients that completed the study, 32 intervention (INT) and 31 control (CTRL). Patients were similar in age (70\u00b112 vs 69\u00b113y), NYHA class (II 81 vs 87%), patients with ejection fraction &lt;40% (56 vs 48%) and comorbidities such as diabetes (38 vs 45%; INT vs CTRL).<\/p>\n<p>The CONTINUUM program is a partnership between the\u00a0<span class=\"xn-location\">Centre<\/span>\u00a0hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM), the CHUM Research Centre, MEDTEQ+, Greybox Solutions Inc., Mitacs, PROMPT, and Boehringer Ingelheim (<span class=\"xn-location\">Canada<\/span>) Ltd.\/ Lt\u00e9e. Boehringer Ingelheim (<span class=\"xn-location\">Canada<\/span>) Ltd. had no role in the design or conduct of the study.<\/p>\n<p><b>About CHUM<br class=\"dnr\" \/><\/b>The\u00a0<span class=\"xn-location\">Centre<\/span>\u00a0hospitalier de l\u2019Universit\u00e9\u00a0de\u00a0<span class=\"xn-location\">Montreal<\/span>\u00a0(CHUM) is an innovative hospital devoted to serving patients and the\u00a0<span class=\"xn-location\">Quebec<\/span>\u00a0population. The CHUM adopts an integrated approach to health and the population which is expressed in all aspects of its mission such as, care, teaching, research, management and innovation, as well as in partnership with the patient and citizen (SERGIP). To achieve the objective of continuous improvement in the health of the population, management of the care trajectory and the life trajectory of patients has been implemented using data analyzed by artificial intelligence from genetic and environmental information. In collaboration with other speakers in the health and social services network (RSSS), the CHUM offers the best specialized care and services based on constantly updated scientific knowledge.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=1817567752&amp;u=http%3A%2F%2Fwww.chumontreal.qc.ca%2F&amp;a=chumontreal.qc.ca\" target=\"_blank\" rel=\"nofollow noopener\">chumontreal.qc.ca<\/a><\/p>\n<p><b>About Greybox Solutions Inc.<br class=\"dnr\" \/><\/b>Greybox Solutions Inc., a\u00a0<span class=\"xn-location\">Montreal<\/span>-based healthcare technology company, is a pioneer in the development of Digital Therapies (DTx). Integrating a multitude of technologies within its Takecare platform \u2013 versatile, accessible and revolutionary \u2013 Greybox offers a modern solution to the numerous and complex challenges at the heart of the healthcare system. Creator of a technological solution offering a simple and dynamic alternative for monitoring chronic diseases, Greybox Solutions, in partnership with the Centre Hospitalier de l\u2019Universit\u00e9 de Montr\u00e9al (CHUM) and Boehringer Ingelheim Canada, has clinically demonstrated the effectiveness of its DTx solution in the field of heart failure. Clinical applications are currently being evaluated in the areas of healthcare related to heart disease, lung disease, mental health and newborn care, among others.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=3680476640&amp;u=http%3A%2F%2Fwww.greybox.ca%2F&amp;a=www.greybox.ca\" target=\"_blank\" rel=\"nofollow noopener\">www.greybox.ca<\/a><\/p>\n<p><b>About MEDTEQ+<br class=\"dnr\" \/><\/b>MEDTEQ+, a pan-Canadian consortium for industrial research and innovation in healthcare technologies,\u00a0aims to accelerate the development of innovative technological solutions to improve people\u2019s health and\u00a0quality of life. MEDTEQ+ supports the validation of these technologies, their integration into the healthcare\u00a0network, their commercialization, as well as their local and international outreach, by bringing together the\u00a0complementary skills of industrial and institutional partners and healthcare providers. MEDTEQ+ offers\u00a0support, subsidies, and investment services to innovative companies. Since\u00a0<span class=\"xn-chron\">December 2022<\/span>, MEDTEQ+\u00a0has also been the lead partner in the envisAGE initiative, which aims to catalyze the AgeTech ecosystem\u00a0and help companies grow and scale in the AgeTech market. MEDTEQ+ relies, among other things, on\u00a0financial support from the Government of\u00a0<span class=\"xn-location\">Quebec<\/span>, the Government of\u00a0<span class=\"xn-location\">Canada<\/span>, the private sector, and\u00a0complementary partners to foster research-industry relationships.\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=693964030&amp;u=http%3A%2F%2Fwww.medteq.ca%2F&amp;a=www.medteq.ca\" target=\"_blank\" rel=\"nofollow noopener\">www.medteq.ca<\/a><\/p>\n<p><b>Boehringer Ingelheim (<span class=\"xn-location\">Canada<\/span>) Ltd.<br class=\"dnr\" \/><\/b>Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. As a leading research-driven biopharmaceutical company, the company creates value through innovation in areas of high unmet medical need. Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units, Human Pharma and Animal Health. The Canadian headquarters of Boehringer Ingelheim was established in 1972 in\u00a0<span class=\"xn-location\">Montreal, Quebec<\/span>\u00a0and is now located in\u00a0<span class=\"xn-location\">Burlington, Ontario<\/span>. Boehringer Ingelheim employs approximately 500 people across\u00a0<span class=\"xn-location\">Canada<\/span>. Learn more at\u00a0<a href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=2594782920&amp;u=http%3A%2F%2Fwww.boehringer-ingelheim.com%2Fca&amp;a=www.boehringer-ingelheim.com%2Fca\" target=\"_blank\" rel=\"nofollow noopener\">www.boehringer-ingelheim.com\/ca<\/a><\/p>\n<div>\n<div class=\"divOverflow\">\n<div class=\"table-responsive\">\n<table class=\"prnbcc\" border=\"0\" width=\"\" cellspacing=\"0\" cellpadding=\"1\">\n<tbody>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b>___________________________<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\"><b>References<\/b><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\"><\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\">1 Emmanuel Marier Tetrault NP, et al. The Impact of Remote Patient Monitoring and Digital Therapeutics on Major Clinical Events and Costs in Heart Failure Patients: Early Experience in the Quebec Public Healthcare System. Presented at the American Heart Association\u2019s Scientific Sessions 2023; 12 November 2023. Available at:\u00a0<a class=\"prnews_a\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=3094232892&amp;u=https%3A%2F%2Fdoi.org%2F10.1161%2Fcirc.148.suppl_1.12585&amp;a=https%3A%2F%2Fdoi.org%2F10.1161%2Fcirc.148.suppl_1.12585Circulation.+2023%3B148%3AA12585\" target=\"_blank\" rel=\"nofollow noopener\">https:\/\/doi.org\/10.1161\/circ.148.suppl_1.12585Circulation. 2023;148:A12585<\/a><\/span><\/p>\n<\/td>\n<\/tr>\n<tr>\n<td class=\"prngen2\" colspan=\"1\" rowspan=\"1\" width=\"\" height=\"\">\n<p class=\"prnml4 dnr\"><span class=\"prnews_span\">2 Heart and Stroke Foundation. Heart failure in Canada: complex, incurable and on the rise. Available at:\u00a0<a class=\"prnews_a\" href=\"https:\/\/c212.net\/c\/link\/?t=0&amp;l=en&amp;o=4028215-1&amp;h=4137382592&amp;u=https%3A%2F%2Fwww.heartandstroke.ca%2Fwhat-we-do%2Fmedia-centre%2Fnews-releases%2Fheart-failure-in-canada-complex-incurable-and-on-the-rise&amp;a=Heart+failure+in+Canada+complex+incurable+and+on+the+rise+%7C+Heart+and+Stroke+Foundation\" target=\"_blank\" rel=\"nofollow noopener\">Heart failure in Canada complex incurable and on the rise | Heart and Stroke Foundation<\/a>. Accessed November 2023.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/div>\n<\/div>\n<\/div>\n<p><strong>SOURCE Boehringer Ingelheim Canada LTD.<\/strong><\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n<\/article>\n<\/div>\n<\/div>\n<p><strong>For further information:<\/strong><\/p>\n<p>MEDIA CONTACTS: Andr\u00e9e-Anne Toussaint, Communication Advisor, Centre hospitalier de l&#8217;Universit\u00e9 de Montr\u00e9al (CHUM), Email:\u00a0andree-anne.toussaint.chum@ssss.gouv.qc.ca, Telephone: 514 890-8000, extension 23675; Anne Coffey, Corporate Communications, Boehringer Ingelheim (Canada) Ltd., Email:\u202fanne.coffey@boehringer-ingelheim.com, Telephone: 416-526-5388[\/vc_column_text][\/vc_column][\/vc_row]<\/p>\n","protected":false},"excerpt":{"rendered":"<p>Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients A remote patient monitoring mobile app and a digital therapeutics solution demonstrates its impact for the Quebec Public Healthcare System Heart failure outpatients achieved a significant reduction in emergency room visits and\/or hospitalizations Detailed data were presented at the 2023 [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":2544,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[15],"tags":[],"class_list":["post-3861","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-nouvelle"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+\" \/>\n<meta property=\"og:description\" content=\"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients A remote patient monitoring mobile app and a digital therapeutics solution demonstrates its impact for the Quebec Public Healthcare System Heart failure outpatients achieved a significant reduction in emergency room visits and\/or hospitalizations Detailed data were presented at the 2023 [&hellip;]\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/\" \/>\n<meta property=\"og:site_name\" content=\"MEDTEQ+\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-22T18:41:23+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-01-20T21:51:11+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"399\" \/>\n\t<meta property=\"og:image:height\" content=\"238\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"boreale_user\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@medteq_ca\" \/>\n<meta name=\"twitter:site\" content=\"@medteq_ca\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"boreale_user\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"7 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/\"},\"headline\":\"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients\",\"datePublished\":\"2023-11-22T18:41:23+00:00\",\"dateModified\":\"2025-01-20T21:51:11+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/\"},\"wordCount\":1203,\"publisher\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg\",\"articleSection\":[\"Nouvelle\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/\",\"name\":\"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg\",\"datePublished\":\"2023-11-22T18:41:23+00:00\",\"dateModified\":\"2025-01-20T21:51:11+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg\",\"contentUrl\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2025\\\/01\\\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg\",\"width\":399,\"height\":238,\"caption\":\"MEDTEQ+ - Innover pour la sant\u00e9\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#website\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/\",\"name\":\"MEDTEQ+\",\"description\":\"Innovation for health\",\"publisher\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#organization\"},\"alternateName\":\"MEDTEQ+\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#organization\",\"name\":\"MEDTEQ+\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/medteq-new-logo.png\",\"contentUrl\":\"https:\\\/\\\/www.medteq.ca\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/medteq-new-logo.png\",\"width\":505,\"height\":70,\"caption\":\"MEDTEQ+\"},\"image\":{\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/x.com\\\/medteq_ca\",\"https:\\\/\\\/www.linkedin.com\\\/company\\\/medteq-plus\\\/\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/#\\\/schema\\\/person\\\/deecfd9589f1fadb79527a1f888d8cc5\",\"name\":\"boreale_user\",\"url\":\"https:\\\/\\\/www.medteq.ca\\\/en\\\/author\\\/boreale\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/","og_locale":"en_US","og_type":"article","og_title":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+","og_description":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients A remote patient monitoring mobile app and a digital therapeutics solution demonstrates its impact for the Quebec Public Healthcare System Heart failure outpatients achieved a significant reduction in emergency room visits and\/or hospitalizations Detailed data were presented at the 2023 [&hellip;]","og_url":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/","og_site_name":"MEDTEQ+","article_published_time":"2023-11-22T18:41:23+00:00","article_modified_time":"2025-01-20T21:51:11+00:00","og_image":[{"width":399,"height":238,"url":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg","type":"image\/jpeg"}],"author":"boreale_user","twitter_card":"summary_large_image","twitter_creator":"@medteq_ca","twitter_site":"@medteq_ca","twitter_misc":{"Written by":"boreale_user","Est. reading time":"7 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#article","isPartOf":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/"},"headline":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients","datePublished":"2023-11-22T18:41:23+00:00","dateModified":"2025-01-20T21:51:11+00:00","mainEntityOfPage":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/"},"wordCount":1203,"publisher":{"@id":"https:\/\/www.medteq.ca\/en\/#organization"},"image":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg","articleSection":["Nouvelle"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/","url":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/","name":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients | MEDTEQ+","isPartOf":{"@id":"https:\/\/www.medteq.ca\/en\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#primaryimage"},"image":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#primaryimage"},"thumbnailUrl":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg","datePublished":"2023-11-22T18:41:23+00:00","dateModified":"2025-01-20T21:51:11+00:00","breadcrumb":{"@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#primaryimage","url":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg","contentUrl":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2025\/01\/Boehringer_Ingelheim_Canada_LTD__R_duction_de_visites___l_urgenc.jpg","width":399,"height":238,"caption":"MEDTEQ+ - Innover pour la sant\u00e9"},{"@type":"BreadcrumbList","@id":"https:\/\/www.medteq.ca\/en\/innovative-digital-therapeutics-program-shows-a-reduction-in-hospitalizations-and-costs-for-heart-failure-patients\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.medteq.ca\/en\/"},{"@type":"ListItem","position":2,"name":"Innovative digital therapeutics program shows a reduction in hospitalizations and costs for heart failure patients"}]},{"@type":"WebSite","@id":"https:\/\/www.medteq.ca\/en\/#website","url":"https:\/\/www.medteq.ca\/en\/","name":"MEDTEQ+","description":"Innovation for health","publisher":{"@id":"https:\/\/www.medteq.ca\/en\/#organization"},"alternateName":"MEDTEQ+","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.medteq.ca\/en\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.medteq.ca\/en\/#organization","name":"MEDTEQ+","url":"https:\/\/www.medteq.ca\/en\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.medteq.ca\/en\/#\/schema\/logo\/image\/","url":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2024\/11\/medteq-new-logo.png","contentUrl":"https:\/\/www.medteq.ca\/wp-content\/uploads\/2024\/11\/medteq-new-logo.png","width":505,"height":70,"caption":"MEDTEQ+"},"image":{"@id":"https:\/\/www.medteq.ca\/en\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/x.com\/medteq_ca","https:\/\/www.linkedin.com\/company\/medteq-plus\/"]},{"@type":"Person","@id":"https:\/\/www.medteq.ca\/en\/#\/schema\/person\/deecfd9589f1fadb79527a1f888d8cc5","name":"boreale_user","url":"https:\/\/www.medteq.ca\/en\/author\/boreale\/"}]}},"_links":{"self":[{"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/posts\/3861","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/comments?post=3861"}],"version-history":[{"count":1,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/posts\/3861\/revisions"}],"predecessor-version":[{"id":4349,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/posts\/3861\/revisions\/4349"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/media\/2544"}],"wp:attachment":[{"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/media?parent=3861"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/categories?post=3861"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.medteq.ca\/en\/wp-json\/wp\/v2\/tags?post=3861"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}